Glioma Stem Cell-Targeted Dendritic Cells as a Tumor Vaccine Against Malignant Glioma.
- Author:
Baowei JI
1
;
Qianxue CHEN
;
Baohui LIU
;
Liquan WU
;
Daofeng TIAN
;
Zhentao GUO
;
Wei YI
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: Glioma; cancer stem cell; dendritic cell; vaccine
- MeSH: Animals; Antigens, Neoplasm/immunology; Apoptosis; Brain Neoplasms/*therapy; Cancer Vaccines/*therapeutic use; Cell Line, Tumor; Cell Proliferation; Dendritic Cells/*cytology; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glioma/*therapy; Humans; Interferon-gamma/metabolism; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplastic Stem Cells/*cytology; T-Lymphocytes, Cytotoxic/immunology
- From:Yonsei Medical Journal 2013;54(1):92-100
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Cancer stem cells have recently been thought to be closely related to tumor development and reoccurrence. It may be a promising way to cure malignant glioma by using glioma stem cell-targeted dendritic cells as a tumor vaccine. In this study, we explored whether pulsing dendritic cells with antigens of glioma stem cells was a potent way to induce specific cytotoxic T lymphocytes and anti-tumor immunity. MATERIALS AND METHODS: Cancer stem cells were cultured from glioma cell line U251. Lysate of glioma stem cells was obtained by the repeated freezing and thawing method. Dendritic cells (DCs) were induced and cultured from the murine bone marrow cells, the biological characteristics were detected by electron microscope and flow cytometry. The DC vaccine was obtained by mixing DCs with lysate of glioma stem cells. The DC vaccine was charactirizated through the mixed lymphocyte responses and cell killing experiment in vitro. Level of interferon-gamma (IFN-gamma) in the supernatant was checked by ELISA. RESULTS: After stimulation of lysate of glioma stem cell, expression of surface molecules of DC was up-regulated, including CD80, CD86, CD11C and MHC-II. DCs pulsed with lysate of glioma stem cells were more effective than the control group in stimulating original glioma cells-specific cytotoxic T lymphocytes responses, killing glioma cells and boosting the secretion of IFN-gamma in vitro. CONCLUSION: The results demonstrated DCs loaded with antigens derived from glioma stem cells can effectively stimulate naive T cells to form specific cytotoxic T cells, kill glioma cells cultured in vitro.
